{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-000683","form_type":"8-K","ticker":"TECH","cik":"0000842023","company_name":"BIO-TECHNE Corp","filed_at":"2024-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.037602+00:00","generated_at":"2026-06-06T12:19:43.215405+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bio-Techne Q2 organic revenue down 2% to $272.6M; GAAP EPS $0.17 vs $0.31 YoY; declares $0.08 dividend","bullets":["Q2 organic revenue declined 2% to $272.6M; reported revenue flat vs prior year.","GAAP EPS $0.17 vs $0.31 YoY; adjusted EPS $0.40 vs $0.47.","Cash flow from operations $142.5M, up 18% YoY.","Board declared $0.08 per share quarterly dividend, payable Feb 26, 2024.","Dr. Matthew F. McManus appointed President of Diagnostics and Genomics segment."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-000683","json":"https://secwatch.observer/filing/0001558370-24-000683.json","markdown":"https://secwatch.observer/filing/0001558370-24-000683.md","text":"https://secwatch.observer/filing/0001558370-24-000683.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/842023/000155837024000683/0001558370-24-000683-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/842023/000155837024000683/tmb-20240201x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T12:19:43.215405+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d213be2b1f907356338ae866a892dac9fac8bc21","claim":"BIO-TECHNE Corp reported financial results for second quarter ended December 31, 2023.","evidence_excerpt":"A copy of the press release issued by Bio-Techne Corporation on February 1, 2024, describing the results of operations for the quarter ended December 31, 2023, and its financial condition as of December 31, 2023 is attached hereto as Exhibit 99.1.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/842023/000155837024000683/0001558370-24-000683-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}